Intellectual Property
Patent Portfolio
GlycoNex's glycan-directed oncology programs are protected by 36 granted patents across multiple jurisdictions, plus published and pending applications. Granted patent numbers and titles are listed below for partner due diligence.
GNX102 / GNX1021 Antibody Family
The anti-branched Lewis B/Y therapeutic antibody behind lead ADC GNX1021, together with its antibody-drug conjugate composition and method-of-use applications.
Granted patents (9)
| Jurisdiction | Patent Title | Patent No. |
|---|---|---|
| US | Therapeutic antibodies | US11440967B2 |
| US | Therapeutic antibodies | US11643471B2 |
| CN | Therapeutic antibodies binding to biantennary Lewis B and Lewis Y antigens | CN112533948B |
| JP | Therapeutic antibodies binding to biantennary Lewis B and Lewis Y antigens | JP7696404B2 |
| KR | Therapeutic antibodies binding to biantennary Lewis B and Lewis Y antigens | 10-2480815 |
| TW | Therapeutic antibodies | I842712 |
| MX | Therapeutic antibodies binding to biantennary Lewis B and Lewis Y antigens | 424537 |
| RU | Therapeutic antibodies binding to biantennary Lewis B and Lewis Y antigens | 2803097 |
| IL | Therapeutic antibodies binding to biantennary Lewis B and Lewis Y antigens | 279109 |
GNX8
An anti-extended type I glycosphingolipid antibody covered by 27 granted patents worldwide.
Representative grants (6 of 27)
| Jurisdiction | Patent Title | Patent No. |
|---|---|---|
| US | Anti-extended type I glycosphingolipid antibody, derivatives thereof and use | US 8163497 B2 |
| EP | Anti-extended type I glycosphingolipid antibody, derivatives thereof and use | EP 2324060 B1 |
| JP | Anti-extended type I glycosphingolipid antibody, derivatives thereof and use | JP 5611210 B2 |
| TW | Anti-extended type I glycosphingolipid antibody, derivatives thereof and use | TW I433684 B |
| CN | Anti-extended type I glycosphingolipid antibody, derivatives thereof and use | CN 102282172 B |
| KR | Anti-extended type I glycosphingolipid antibody, derivatives thereof and use | KR 101442323 B1 |
The six grants shown are representative of one patent family registered across 27 jurisdictions; titles are given in English, and the Japanese, Korean and Chinese registers hold the same title in their local language.